127 related articles for article (PubMed ID: 1390307)
21. A mucinous-like carcinoma-associated antigen (MCA) in the tissue and blood of patients with primary breast cancer.
Bombardieri E; Gion M; Mione R; Dittadi R; Bruscagnin G; Buraggi G
Cancer; 1989 Feb; 63(3):490-5. PubMed ID: 2643453
[TBL] [Abstract][Full Text] [Related]
22. CEA, MCA, CA 15.3 and CA 549 and their combinations in expressing and monitoring metastatic breast cancer: a prospective comparative study.
Martoni A; Zamagni C; Bellanova B; Zanichelli L; Vecchi F; Cacciari N; Strocchi E; Pannuti F
Eur J Cancer; 1995 Sep; 31A(10):1615-21. PubMed ID: 7488411
[TBL] [Abstract][Full Text] [Related]
23. Is tissue polypeptide antigen still a useful tumor marker in breast carcinoma? Comparison with CA15.3 and MCA.
Gion M; Mione R; Gatti C; Dittadi R; Leon A; Nascimben O; Pizzorno B; Bruscagnin G
Tumori; 1990 Aug; 76(4):360-4. PubMed ID: 2399565
[TBL] [Abstract][Full Text] [Related]
24. Mucin-like carcinoma-associated antigen (MCA) in tissue and serum of patients with breast cancer: clinical applications in prognosis and disease monitoring.
Molina R; Jo J; Filella X; Zanon G; Grau JJ; Joseph J; Bedini JL; Biete A; Ballesta AM
Int J Biol Markers; 1993; 8(2):113-23. PubMed ID: 8366294
[TBL] [Abstract][Full Text] [Related]
25. Clinical evaluation of a new tumour marker TAG 12 in breast cancer.
Eskelinen M; Hippeläinen M; Carlsson L; Jonsson P
Anticancer Res; 1991; 11(2):805-8. PubMed ID: 2064336
[TBL] [Abstract][Full Text] [Related]
26. Nonlinearity of measurements of a tumor marker for breast cancer.
Cooper EH; Forbes MA; Laurence V; Beya MF; de Chastonay J
Clin Chem; 1990 Feb; 36(2):408-9. PubMed ID: 2406045
[No Abstract] [Full Text] [Related]
27. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
[TBL] [Abstract][Full Text] [Related]
28. MCA serum determination in breast carcinoma patients for the diagnosis of bone metastases.
Dominguez-Gadea L; Martin-Curto LM; Crespo A; Avila C
Int J Biol Markers; 1993; 8(4):203-7. PubMed ID: 8138659
[TBL] [Abstract][Full Text] [Related]
29. CA 15.3: early results of a new breast cancer marker.
Colomer R; Sole LA; Navarro M; Encabo G; Ruibal A; Salvador L
Anticancer Res; 1986; 6(4):683-4. PubMed ID: 3463242
[TBL] [Abstract][Full Text] [Related]
30. Serum CEA, CA 15-3, and MCA in breast cancer patients: a clinical evaluation.
Repetto L; Onetto M; Gardin G; Costanzi B; Giudici S; Vitiello E; Merlini L; Naso C; Zannini C; Paganuzzi M
Cancer Detect Prev; 1993; 17(3):411-5. PubMed ID: 8402728
[TBL] [Abstract][Full Text] [Related]
31. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
[TBL] [Abstract][Full Text] [Related]
32. Efficient test for cancer antigens: decreased levels of cancer antigen in serum after excision of breast tumor.
Eskelinen M; Tikanoja S; Collan Y
Anticancer Res; 1989; 9(2):437-9. PubMed ID: 2751269
[TBL] [Abstract][Full Text] [Related]
33. [Correlation of serum concentrations of BCM and MCA, CA 549 and CA 15.3 in women with macrocystic disease of breast].
Vizoso F; Roiz MC; Allende MT; Ruibal A
Med Clin (Barc); 1990 Mar; 94(8):319. PubMed ID: 2342398
[No Abstract] [Full Text] [Related]
34. Value of CA 15:3 in the follow-up of breast cancer patients.
Pons-Anicet DM; Krebs BP; Mira R; Namer M
Br J Cancer; 1987 May; 55(5):567-9. PubMed ID: 3475109
[TBL] [Abstract][Full Text] [Related]
35. A new biomarker in monitoring breast cancer: CA 549.
Beveridge RA; Chan DW; Bruzek D; Damron D; Bray KR; Gaur PK; Ettinger DS; Rock RC; Shurbaji MS; Kuhajda FP
J Clin Oncol; 1988 Dec; 6(12):1815-21. PubMed ID: 3058875
[TBL] [Abstract][Full Text] [Related]
36. Comparison of mammary serum antigen (MSA) and CA15-3 levels in the serum of patients with breast cancer.
Sacks NP; Stacker SA; Thompson CH; Collins JP; Russell IS; Sullivan JA; McKenzie IF
Br J Cancer; 1987 Dec; 56(6):820-4. PubMed ID: 2449238
[TBL] [Abstract][Full Text] [Related]
37. Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease.
Colomer R; Ruibal A; Salvador L
Cancer; 1989 Oct; 64(8):1674-81. PubMed ID: 2790682
[TBL] [Abstract][Full Text] [Related]
38. The role of a new monoclonal antibody assay in the detection of recurrent breast cancer.
Tommasi M; Fantappié B; Distante V; Cataliotti L; Neri B; Ciatto S; Pacini P
Int J Biol Markers; 1986; 1(2):81-4. PubMed ID: 3480914
[TBL] [Abstract][Full Text] [Related]
39. Adenocarcinoma of the uterine cervix. Prognostic significance of pretreatment serum CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen levels in relation to clinical and histopathologic tumor characteristics.
Duk JM; De Bruijn HW; Groenier KH; Fleuren GJ; Aalders JG
Cancer; 1990 Apr; 65(8):1830-7. PubMed ID: 2317761
[TBL] [Abstract][Full Text] [Related]
40. Expression of monoclonal antibody-defined tumor markers in four carcinomas.
Wu JT
Ann Clin Lab Sci; 1989; 19(1):17-26. PubMed ID: 2916833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
